ITPKB and cancer: Previous studies have reported that the ITPKB product, IP4, can effectively inhibit NOX4 activity in cisplatin-resistant cancer cells.20 In TMZ-resistant cells, we observed a significant decrease in IP4 levels after ITPKB knockdown (Fig. 3m and Supplementary Fig. 3x).